Durata Therapeutics, Inc.
89 Headquarters Plaza North
Suite 306
Morristown
New Jersey
07960
United States
Tel: 646-871-6480
Fax: 973-993-4865
Website: http://www.duratatherapeutics.com/
87 articles about Durata Therapeutics, Inc.
-
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
9/6/2018
Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B.
-
Iterum Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) to initiate an initial public offering (IPO). The company hopes to raise $92 million.
-
PDL BioPharma, Inc. Announces Successful Conclusion Of Debt Financing Agreement With Durata Therapeutics, Inc.
11/19/2014
-
Karmanos Cancer Institute Honored By Michigan Cancer Consortium With Spirit Of Collaboration Award
11/18/2014
-
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
11/17/2014
-
Actavis And Durata Therapeutics, Inc. Receive U.S. FTC Clearance For Actavis' Proposed Acquisition Of Durata
11/3/2014
-
Durata Therapeutics, Inc. Presents New Data For DALVANCEā¢ At IDWeek 2014
10/13/2014
-
Actavis Finally Makes A Move, Pays $675 Million For Durata Therapeutics, Inc.
10/6/2014
-
FDA Grants Durata Therapeutics, Inc. A Special Protocol Agreement (SPA) For Its Phase 3 Study Of DALVANCE(TM) In Hospitalized Community-Acquired Pneumonia
10/3/2014
-
Durata Therapeutics, Inc. To Present Five Posters At IDWeek 2014
10/2/2014
-
Durata Therapeutics, Inc. Presented Data At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC)
9/9/2014
-
Durata Therapeutics, Inc. To Present Safety And Efficacy Data At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC)
9/3/2014
-
Durata Therapeutics, Inc. Names Wendy Yarno And J. Martin Carroll To Its Board Of Directors
8/27/2014
-
Durata Therapeutics, Inc. Reports Second Quarter 2014 Financial Results
8/7/2014
-
Durata Therapeutics, Inc. To Present At Upcoming Investor Conference
8/6/2014
-
Durata Therapeutics, Inc. To Report Second Quarter 2014 Financial Results On August 7, 2014
7/31/2014
-
Durata Therapeutics, Inc. Enters Into An Exclusive License And Supply Agreement With Angelini To Commercialize Dalbavancin In Certain European Territories, Russia And Turkey
7/30/2014
-
Durata Therapeutics, Inc. Announces The U.S. Launch Of Dalvanceā¢
7/18/2014
-
Durata Therapeutics, Inc. To Present At Upcoming Investor Conferences
6/17/2014
-
The New England Journal of Medicine Publishes Data From Durata Therapeutics, Inc. 's Discover Program
6/5/2014